Lilly pharmaceutical

Eli Lilly is the top 10 multinational pharmaceutical company in the world. Projects jointly developed by Suzhou Yabao and Eli Lilly include sy-004, sy-008 and sy-009. SY-004 and Hualin medicine hypoglycemic drug zaloglitin are all new GKA drugs, the indication for treatment is type 2 diabetes. At present, sy-004 is in phase II clinical research stage and will enter phase III clinical research in 2022. SY-008/009 is a SGLT1 inhibitor and belongs to the global first-in- class drug. The indication for treatment is type 2 diabetes, and is currently in the phase of clinical Ib research.

Next:University of South Australia